Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q13507
UPID:
TRPC3_HUMAN
Alternative names:
Transient receptor protein 3
Alternative UPACC:
Q13507; A7VJS1; E9PCJ9; O00593; Q15660; Q52M35; Q5G1L5
Background:
Short transient receptor potential channel 3 (TRPC3), also known as Transient receptor protein 3, plays a crucial role in cellular functions by forming a receptor-activated non-selective calcium permeant cation channel. This channel is pivotal in various signaling pathways, activated by receptor tyrosine kinases or G-protein coupled receptors, influencing intracellular calcium levels.
Therapeutic significance:
TRPC3's involvement in Spinocerebellar ataxia 41, a disorder characterized by progressive incoordination and degeneration of the cerebellum, highlights its potential as a therapeutic target. Understanding the role of TRPC3 could open doors to potential therapeutic strategies for treating this debilitating condition.